Servier receives a positive CHMP opinion for ONIVYDE® in combination with oxaliplatin, fluorouracil and leucovorin (NALIRIFOX) as first line therapy in patients with metastatic pancreatic adenocarcinoma.
Discover our news
Servier Receives Regulatory Filing Acceptances from FDA and EMA for Vorasidenib in the Treatment of IDH-Mutant Diffuse Glioma
CStone sells to Servier its exclusive rights to TIBSOVO®in Greater China and Singapore
Servier Showcases Leadership in Mutant Isocitrate Dehydrogenase (IDH) Inhibition Through New Data Spotlighting Real-World Treatment Patterns and Clinical Outcomes of Tibsovo® Use at ASH 2023
Servier Expands Base4 Partnership to Advance Neuroscience Drug Development
Nicolas Garnier joins Servier as Chief Patient Officer
Data at ASH 2023 Underscores Servier Leadership in Hard-to-Treat Hematologic Malignancies
New Analyses from Pivotal Phase 3 INDIGO Study Reinforce Vorasidenib’s Potential to Change the Treatment Paradigm for IDH-Mutant Diffuse Glioma
New Vorasidenib Data at SNO 2023 Bolster Servier’s Neuro-Oncology Clinical Development Program